BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel


NEWSLETTERS
FREENewsletters
Archive

NEWS
News bySubject
News byDisease
News byDate
PLoS
SearchNews

CAREER NETWORK
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

DIVERSITY

HOTBEDS
Regional News
BiotechBay™
BiotechBeach™
Genetown™
PharmCountry™
BioCapital™
BioMidwest™
BioNC™
BioForest™
SouthernPharm™
BioCanadaEast™
US Device™

INVESTOR
Market Summary
News
IPOs

PROFILES
CompanyProfiles

START UPS
Companies
Events

INTELLIGENCE
BioPharm Insight

INDUSTRY EVENTS
Biotech Events
Post an Event

RESOURCES
RealEstate
Business Opportunities
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Vernalis Plc Sponsored ADR (OP: VNLPY)
0.7300 USD  UNCHANGED
Last Price  /  Updated: 8:10 PM EDT, Apr 18, 2013  /  Add to My Watchlist      
View: Quote News
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.7300
Today's Range 0.7300 - 0.7300
52wk Range 0.5800 - 0.7300
Shares Outstanding 221,056,500
Dividend Yield N/A
Top News
More News
Vernalis announces clinical update on partnered compounds AUY922 and HSP990
December 14, 2009
Vernalis plc (LSE: VER) today announces that at its 9 December 2009 Oncology and Pipeline Update, Novartis provided an update on the clinical status of two Hsp90 inhibitors (AUY922 and HSP990), which... Read More
category Announcement , Healthcare , Biotechnology and Drugs
from 1888PressRelease - Full Feed
Vernalis Earns Milestone Payment in connection with its 2008 sale of Apokyn and its US commercial operations
December 14, 2009
Vernalis plc (LSE: VER) today announces it will receive US$700,000 as further consideration for the sale to Ipsen of Apokyn and its US Commercial Operations announced in June 2008. Read More
category Healthcare , Biotechnology and Drugs , Report
from 1888PressRelease - Full Feed

More News
Read More
Interim Management Statement for the period to 12 November 2009
December 14, 2009
category Healthcare , Biotechnology and Drugs , Statement
from 1888PressRelease - Full Feed
Vernalis initiates Pilot Study of V3381 in patients with chronic cough
October 07, 2009
category Healthcare , Study , Biotechnology and Drugs
from 1888PressRelease - Full Feed
Announcement of Interim results for the six months ended 30 June 2009
August 07, 2009
category Healthcare , Biotechnology and Drugs , Report
from 1888PressRelease - Full Feed
Vernalis and GlaxoSmithKline enter into a collaboration, option and license agreement over a novel Vernalis oncology programme
August 07, 2009
category Collaboration , Healthcare , Biotechnology and Drugs
from 1888PressRelease - Full Feed
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
About BioSpace | Contact Us | Privacy Statement | Terms of Use
Post Your News | Post Event | Post Jobs | Post Company Profile | Advertising Opportunities

RSS FEED All News | Breaking News | Featured Stories

© 2007 BioSpace, Inc - an onTargetjobs company
Visit other onTargetjobs companies
Niche Job Boards | Biotechnology Jobs | Healthcare Jobs | Nursing Jobs | Accounting Jobs | Hospitality Jobs
Hospitality Jobs Canada | Hospitality Jobs UK